EGFR and non-small cell lung carcinoma: In this study, Ibr‐7 exhibited its dual inhibitory activity towards EGFR and mTORC1/S6, and displaying enhanced cytotoxicity against NSCLC cells; these results will provide meaningful insights into the development of novel BTK inhibitors.